CMS Drops Proposal To Change Part D Protected Drug Classes
This article was originally published in The Pink Sheet Daily
Executive Summary
In a letter to Congress, CMS Administrator Tavenner says that due to strong opposition from members of Congress and stakeholders, it will not finalize several controversial proposals in its recent draft rule for Medicare Part D, including removal of special formulary protection for three drug classes.
You may also be interested in...
Trump Drug Pricing Plan Includes Part D Surprises, Challenges PBM Business Model
The reform 'blueprint' might actually live up to its hype.
Trump Drug Pricing Plan Includes Part D Surprises, Challenges PBM Business Model
The reform 'blueprint' might actually live up to its hype.
CMS Efforts On Value-Based Payments Should Focus On Removing Barriers, PhRMA Says
The Pharmaceutical Research and Manufacturers of America says the US Centers for Medicare and Medicaid Services should not itself initiate experiments with value-based payment approaches. Any demonstrations led by agency's CMMI should focus on "holistic" approaches to health costs.